Foghorn Therapeutics Inc. (FHTX) Year-over-year earnings per share growth for the last twelve months

Symbol and logo of brand Foghorn Therapeutics, Inc. (FHTX)

Foghorn Therapeutics (FHTX) operates in the non-cyclical blood cancer sector, demonstrating resilience to recessions. A unique gene modification method allows the company to claim premium pricing for its drugs. Experienced management maintains investor confidence through partnerships with industry behemoths. The quarterly EPS growth on this chart clearly illustrates profit dynamics, where the value of 419.40 expresses the metric level.

foghorntx.com (FHTX) - Year-over-year earnings per share growth for the last 12 months from 07/04/2022 to 11/16/2026

Analytical breakdowns for Foghorn Therapeutics

- market value and analyst target forecast:
- market capitalization details:
Fundamental company analysis:foghorntx.com - FHTX
Manufactured product of Foghorn Therapeutics

The investment attractiveness of Foghorn Therapeutics (FHTX) is determined by the balance between high R&D expenditures and the potential capitalization of Gene Traffic patents. Quarterly EPS growth measures the change in net income per share, reflecting operational efficiency and the pace of business scaling. By analyzing the quarterly EPS dynamics profile on the GURU.Markets platform, an investor assesses the company's ability to navigate the stringent FDA regulatory filter. A positive trend confirms capital resilience amidst costly clinical trials. This indicator serves as a key marker of the biotech startup's fundamental viability.

Who Foghorn Therapeutics competes with

tgtherapeutics.com (TGTX) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Arcellx Therapeutics (ACLX)|Year-over-year earnings per share growth for the last twelve months Disc Medicine Inc|Earnings per share growth in annualized terms for the last twelve months Syndax Pharmaceuticals SNDX|Quarterly EPS earnings growth KURA|ADC Therapeutics SA - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months vorbio.com VOR|NKTX: Year-over-year earnings per share growth for the last 12 months|COEP - Year-over-year earnings per share growth for the last twelve months|Actinium Pharmaceuticals, Inc. (ATNM) - Year-over-year net earnings per share growth for the last 12 months|ESLA (Estrella Immunopharma) - Year-over-year net earnings per share growth for the last 12 months|CASI - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Marker Bio|Quarterly EPS earnings growth IN8bio, Inc.|Year-over-year earnings per share growth for the last twelve months Eterna Therapeutics Inc (ERNA)|Year-over-year net earnings per share change for the last twelve months gtbiopharma.com|Quarterly EPS earnings growth APTO (Aptose Biosciences)|Quarterly EPS earnings growth Bio-Path BPTH|MEI Pharma Inc - Quarterly EPS earnings growth|VINC (Vincerx Pharma Inc.) - Year-over-year earnings per share growth for the last 12 months